Publication | Open Access

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells

Hematological MalignancyAll-trans-retinoic AcidMedicineMalignant Blood DisorderPharmacologyHuman Leukemia CellsPharmacotherapyAnti-cancer AgentCancer TreatmentChemotherapeutic DrugsOncologyRadiation OncologyTumor MicroenvironmentCancer Research